← Back to patent-cliff list
CAS 105-53-3
diethyl malonateCarbethoxyacetic ester1,3-Diethyl propanedioate
Codes: MRIO-011, (III)638294-4-a, (VI)169995-7-a, (IX)169995-10-a, (IIIb)169995-24-a, Lercanidipine Hydrochloride-017, Tilidine Hydrochloride-002, ALOG-012, ETRA-007, POSA-010, D-RUXO-002, PREG-012 +2 more
Application context (from source-drug indications)
Diabetic neuropathyMirogabalin besilatePostherpetic neuralgiaMirogabalin besilatePeripheral nervous system disorderMirogabalin besilateSystolic heart failureFinerenoneDiastolic heart failureFinerenoneHeart failureFinerenoneChronic renal impairmentFinerenoneDiabetic nephropathyFinerenoneType 2 diabetesFinerenoneContraceptionDrospirenoneStomatitis, aphthousDrospirenonePremenstrual dysphoric disorderDrospirenonePremenstrual syndromeDrospirenoneDysmenorrhoeaDrospirenoneDepressionDrospirenoneEssential hypertensionValsartan/Lercanidipine HydrochloridePainTilidine HydrochlorideType 2 diabetesAlogliptin BenzoateDiabetesAlogliptin BenzoateAcute coronary syndromeAlogliptin BenzoateHIV infectionEtravirineFriedreich's ataxiaEtravirineInflammatory diseaseEtravirineInsulin resistanceEtravirineCandidiasisPosaconazoleAspergillus infectionPosaconazoleFungal infectionPosaconazoleOral candidiasisPosaconazoleCoccidioidomycosisPosaconazoleHistoplasmosisPosaconazoleHypertensionLercanidipine HydrochlorideAlopecia areataDeuterated ruxolitinibRenal impairmentDeuterated ruxolitinibHepatic function declineDeuterated ruxolitinibFibromyalgiaPregabalinSeizurePregabalinPostherpetic neuralgiaPregabalin神经痛PregabalinPartial-onset seizurePregabalinDiabetic neuropathyPregabalinPulmonary tuberculosisTBA-7371Mycobacterium tuberculosis infectionTBA-7371Head and neck squamous cell carcinomaBuparlisibSolid tumourBuparlisib鼻咽肿瘤Buparlisib喉肿瘤Buparlisib口咽肿瘤BuparlisibSquamous cell carcinomaBuparlisib
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Mirogabalin besilate | Tier C — Watch / trade | 2030 |
| Finerenone | Tier C — Watch / trade | 2030 |
| Drospirenone | Tier C — Watch / trade | - |
| Valsartan/Lercanidipine Hydrochloride | Tier C — Watch / trade | - |
| Tilidine Hydrochloride | Tier C — Watch / trade | - |
| Alogliptin Benzoate | Tier C — Watch / trade | - |
| Etravirine | Tier C — Watch / trade | - |
| Posaconazole | Tier C — Watch / trade | - |
| Lercanidipine Hydrochloride | Tier C — Watch / trade | - |
| Deuterated ruxolitinib | Tier C — Watch / trade | - |
| Pregabalin | Tier B — Position early | - |
| TBA-7371 | Tier C — Watch / trade | - |
| Buparlisib | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
(1R,5S)-3-ethylbicyclo[3.2.0]hept-3-en-6-one→diethyl malonate→diethyl 2-((1R,5S)-3-ethylbicyclo[3.2.0]hept-3-en-6-ylidene)malonate→diethyl 2-((1R,5S,6R)-6-cyano-3-ethylbicyclo[3.2.0]hept-3-en-6-yl)malonate→2-((1R,5S,6S)-6-cyano-3-ethylbicyclo[3.2.0]hept-3-en-6-yl)acetic acid→phenylmethanamine 2-((1R,5S,6S)-6-cyano-3-ethylbicyclo[3.2.0]hept-3-en-6-yl)acetate
4-Amino-5-methylpyridin-2(1H)-one→2-Methoxy-4-cyanobenzaldehyde→Carbethoxyacetic ester→Ethyl 4-(4-cyano-2-methoxyphenyl)-2,8-dimethyl-5-oxo-1,4,5,6-tetrahydro-1,6-naphthyridine-3-carboxylate→(Diethoxymethoxy)ethane→Ethyl 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxylate→4-(5-Ethoxy-3-formyl-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-4-yl)-3-methoxybenzonitrile→Ethyl (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxylate→(5aR,10bS)-2-(2,6-Dimethoxyphenyl)-6,10b-dihydro-4H,5aH-indeno[2,1-b][1,2,4]triazolo[4,3-d][1,4]oxazin-2-ium tetrafluoridoborate(1-)
(2R,12S,15S)-12-hydroxy-2,15-dimethyltetracyclo[8.7.0.0(2,7).0(11,15)]heptadec-6-ene-5,14-dione→(2R,12S,15S)-2,15-dimethyl-5,14-dioxotetracyclo[8.7.0.0(2,7).0(11,15)]heptadec-6-en-12-yl acetate→(2R,12S,15S)-5-methoxy-2,15-dimethyl-14-oxotetracyclo[8.7.0.0(2,7).0(11,15)]heptadeca-5,7-dien-12-yl acetate→(3S,5S,7S,11R)-14-methoxy-7,11-dimethylpentacyclo[8.8.0.0(2,7).0(3,5).0(11,16)]octadeca-14,16-dien-6-one→(3'S,5'S,7'S,11'R)-14'-methoxy-7',11'-dimethylspiro[oxirane-2,6'-pentacyclo[8.8.0.0(2,7).0(3,5).0(11,16)]octadecane]-14',16'-diene→Carbethoxyacetic ester→ethyl (3'S,5'S,7'S,11'R)-14'-methoxy-7',11'-dimethyl-5-oxospiro[oxolane-2,6'-pentacyclo[8.8.0.0(2,7).0(3,5).0(11,16)]octadecane]-14',16'-diene-4-carboxylate→ethyl (2S,3'S,5'S,7'S,11'R)-7',11'-dimethyl-5,14'-dioxospiro[oxolane-2,6'-pentacyclo[8.8.0.0(2,7).0(3,5).0(11,16)]octadecane]-15',17'-diene-4-carboxylate→ethyl (2R,4R,10R,14S,15S,16S,18S)-10,14-dimethyl-5',7-dioxospiro[hexacyclo[9.8.0.0(2,4).0(5,10).0(14,19).0(16,18)]nonadecane-15,2'-oxolan]-5-ene-4'-carboxylate
(3aS,3bR,9aR,9bS,11aS)-9a,11a-Dimethyl-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthrene-1,7-dione→(8R,9S,10R,13S,14S)-3-Ethoxy-10,13-dimethyl-1,2,7,8,9,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-one→3-Ethoxy-16-(phenylsulfinyl)androsta-3,5-dien-17-one→16-(Phenylsulfinyl)androst-4-ene-3,17-dione→Androsta-4,15-diene-3,17-dione→(4aR,4bS,6aS,7aS,8aS,8bR,8cR)-4a,6a-Dimethyl-4,4a,4b,6,6a,7a,8,8a,8b,8c,9,10-dodecahydrocyclopropa[4,5]cyclopenta[1,2-a]phenanthrene-2,7(3H,5H)-dione→(4aR,4bS,6aS,7aS,8aS,8bS,8cR)-4a,6a-Dimethyl-4,4a,4b,6,6a,7a,8,8a,8b,8c-decahydrocyclopropa[4,5]cyclopenta[1,2-a]phenanthrene-2,7(3H,5H)-dione→6beta,7beta,15beta,16beta-Dimethylene-17beta-spirooxiranoandrost-4-en-3-one→Carbethoxyacetic ester→(1R,2R,4R,10R,11S,14S,15S,16S,18S,19S)-10,14-Dimethyl-5',7-dioxospiro[hexacyclo[9.8.0.0(2,4).0(5,10).0(14,19).0(16,18)]nonadecane-15,2'-oxolan]-5-ene-4'-carboxylic acid
(1aR,1bR,3S,5aR,5bS,7aS,8aS,9aS,9bS,9cR,9dR)-1b,3-Dihydroxy-5a,7a-dimethylperhydrocyclopropa[4,5]cyclopenta[1,2-a]cyclopropa[l]phenanthren-8-one→(1aR,1bR,3S,5aR,5bS,7aS,8S,8aS,9aS,9bS,9cR,9dR)-5a,7a-Dimethylhexadecahydrospiro[cyclopropa[4,5]cyclopenta[1,2-a]cyclopropa[l]phenanthrene-8,2'-oxirane]-1b,3(2H)-diol→3-(Ethoxycarbonyl)-2-oxopropan-1-ide→Carbethoxyacetic ester→Sodium 3-ethoxy-3-oxopropanoate→(1aR,1bR,3S,5aR,5bS,7aS,8R,8aS,9aS,9bS,9cR,9dR)-1b,3-Dihydroxy-5a,7a-dimethyl-5'-oxoicosahydro-3'H-spiro[cyclopropa[4,5]cyclopenta[1,2-a]cyclopropa[l]phenanthrene-8,2'-furan]-3'-carboxylic acid→Ethyl (1aR,1bR,3S,5aR,5bS,7aS,8R,8aS,9aS,9bS,9cR,9dR)-1b,3-dihydroxy-5a,7a-dimethyl-5'-oxoicosahydro-3'H-spiro[cyclopropa[4,5]cyclopenta[1,2-a]cyclopropa[l]phenanthrene-8,2'-furan]-3'-carboxylate→(1aR,1bR,5aR,5bS,7aS,8R,8aS,9aS,9bS,9cR,9dR)-1b-Hydroxy-5a,7a-dimethyl-3,5'-dioxoicosahydro-3'H-spiro[cyclopropa[4,5]cyclopenta[1,2-a]cyclopropa[l]phenanthrene-8,2'-furan]-3'-carboxylic acid→Ethyl (1aR,1bR,5aR,5bS,7aS,8R,8aS,9aS,9bS,9cR,9dR)-1b-hydroxy-5a,7a-dimethyl-3,5'-dioxoicosahydro-3'H-spiro[cyclopropa[4,5]cyclopenta[1,2-a]cyclopropa[l]phenanthrene-8,2'-furan]-3'-carboxylate→Sodium (1aR,1bR,3S,5aR,5bS,7aS,8R,8aS,9aS,9bS,9cR,9dR)-1b,3-dihydroxy-5a,7a-dimethyl-5'-oxoicosahydro-3'H-spiro[cyclopropa[4,5]cyclopenta[1,2-a]cyclopropa[l]phenanthrene-8,2'-furan]-3'-carboxylate→Sodium (1aR,1bR,5aR,5bS,7aS,8R,8aS,9aS,9bS,9cR,9dR)-1b-hydroxy-5a,7a-dimethyl-3,5'-dioxoicosahydro-3'H-spiro[cyclopropa[4,5]cyclopenta[1,2-a]cyclopropa[l]phenanthrene-8,2'-furan]-3'-carboxylate
Intermediates available on this site
Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.
| Supplier | Product | Price band | MOQ | Lead time | Qualifications | Action |
|---|---|---|---|---|---|---|
| Unibest Nantong cGMP Site | 4-Bromo-2-methoxybenzaldehyde Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | 4-formyl-3-methoxybenzonitrile Pharmaceutical Intermediates | On request | On request | On request | — | |
| Qualified Partner — East China API Works | 4-AMino-5-Methylpyridin-2-ol Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | 2-chloro-5-methylpyridin-4-amine Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | 2-Cyanoethyl 3-oxobutanoate Pharmaceutical Intermediates | On request | On request | On request | — | |
| Qualified Partner — East China API Works | 2-cyanoethyl 4-(4-cyano-2-methoxyphenyl)-2,8-dimethyl-5-oxo-1,4,5,6-tetrahydro-1,6-naphthyridine-3-carboxylate Pharmaceutical Intermediates | On request | On request | On request | — | |
| Qualified Partner — East China API Works | (1R,5S)-3-ethyl-Bicyclo[3.2.0]hept-3-en-6-one Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | 3-ethylbicyclo[3.2.0]hept-3-en-6-one Pharmaceutical Intermediates | On request | On request | On request | — |
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.